is mostly fragmented reports, there are few series, scientific, standardized reports, seriously affecting the quality of life of chest tumor patients. , we have joined experts, the media and medical institutions to help change the status quo.
The first-line treatment of esophageal cancer Keytruda combination therapy was eligible for FDA priority review
Time of Update: 2020-12-31
In this trial, Keytruda's combination therapy with chemotherapy significantly improved the patient's total and non-progressed survival compared to chemotherapy, regardless of whether the patient's tumor expressed PD-L1 and the tumor histological characteristics.
Global esophageal cancer patients in china accounted for half, this treatment is expected to break the multi-year difficulties!
Time of Update: 2020-12-31
series, scientific, standardized reports, seriously affecting the quality of life of chest tumor patients. , we have joined forces with experts, the media and medical institutions to help change the status quo. 39 Health: What will be done
First immunotherapy for esophageal cancer (ESCC)! Best-in-the-hundred Opdivo approved
Time of Update: 2020-12-29
treatment option that extends survival while improving quality of life. this approval, based on phase III ATTRACTION-3 (ONO-4538-24/CA209-473; NCT02569242) study results. data show that Opdivo showed better total lifetime (OS) results
First-line immunotherapy for esophageal cancer! Mercedon Keytrud Plus Chemotherapy Program Receives
Time of Update: 2020-12-25
or metastatic esophageal squamous cell carcinoma (ESCC) with tumor expression PD-L1 (combined positive score (CPS) ≥10). , through its extensive clinical program, is continuing to study Keytruda's therapeutic potential in a variety of environments
Researchers crack 'code' for high incidence of esophageal squamous cancer
Time of Update: 2020-12-16
be screened in Chinese people, and preventive intervention, will make esophageal cancer prevention and early screening possible. "-based" targeted therapy drugs will play an increasingly important role in the treatment of esophageal cancer
Europe's first immunotherapy for esophageal cancer! PaxTrol Opdivo was approved by the European Union
Time of Update: 2020-12-11
lifetime (PFS), disease control rate (DCR), mitigation duration (DOR), and safety assessed by the study investigator. results showed that the study reached the main OS endpoint: Opdivo reduced the risk of death by 23% compared to chemotherapy (HR
Immunotherapy provides long-term survival benefits for more patients with esophageal cancer
Time of Update: 2020-12-05
drug for esophageal cancer, Paboliju monoantigen, was approved in the United States, and in June 2020 Paboliju monoantigen was approved in China for the treatment of patients with second-line advanced esophageal squamous cancer. "Immune therapy
Experts remind: mistakenly swallowing chicken bones giving serious symptoms of esophageal foreign
Time of Update: 2020-11-30
The First Hospital affiliated with the Chinese Medical University quickly organized consultations and diagnosed them as esophageal foreign bodies, accompanied by severe esophageal perforation, vertical abscesses, rupture of infectious thoracic aortic aneurysms, aortic esophageal fistula, esophageal fistula and other conditions.
Esophageal Cancer (ESCC) immunotherapy! Best-in-a-lifetime Opdivo (Odivo) is recommended
Time of Update: 2020-11-02
takes CHMP's advice and makes a final review decision within 2 months. February and June this year, Opdivo was approved in Japan and the United States, respectively, and has so far been approved in five countries for second-line treatment in non
Cell Death Dis: High expression levels of DHODH-β-catenin promote the development of esophageal squamous cell carcinoma.
Time of Update: 2020-10-29
five-year survival rate due to a lack of early diagnosis, limited treatment options and frequent recurrence of the disease. , it is urgent to explore the molecular mechanisms associated with the development of ESCC tumors and to identify molecular
Roche TIGIT monoantigen has been approved in China for clinical joint Tecentriq treatment of esophageal squamous cancer.
Time of Update: 2020-10-15
TIGIT is expressed in a variety of immune cells, including CD8-T cells, CD4-T cells, and NK cells, and is a CD226 co-stimulating receptor-specific negative regulator.
Int J Radiat Oncol Biol Phys: Application of short-range 2D radiotherapy in palliative care for esophageal cancer in developing countries.
Time of Update: 2020-10-13
, the results show that the short-range accelerated radiotherapy, planned and implemented by conventional two-dimensional RT technology, is effective and well-to-bear for the symptoms of local late-stage or metastatic esophageal cancer.
Dig Dis Sci: What are the ineffective predictors of proton pump inhibitors for the treatment of eosinophilic esophagealitis?
Time of Update: 2020-10-12
concluded: Young people, reduced BMI, elevated count of exosome acidophils, and the possible ability to pass endoscopy are all predictive indicators of the lack of response to PPI in EoE patients.
Nat Med: The number of copies of the genome can predict the transformation of esophageal cancer years in advance.
Time of Update: 2020-10-11
Early diagnosis of cancer is one of the best strategies to improve patient survival and reduce treatment-related side effects, however, it carries the risk of overtreated treatment.
Research and development daily first-line treatment of esophageal cancer Keytruda chemotherapy combination reduces the risk of death by 27%
Time of Update: 2020-10-07
-P The D-L1 therapy Tecentriq is used in combination with Avastin to treat adult patients with non-removable or metastatic hepatocellular carcinoma who have not previously received systematic treatment, as well as alexion company ULTOMIRIS® a new 100 mg/mL intravenously improved formula. .
Stomach cancer esophageal cancer is heavy! The combined chemotherapy first-line treatment
Time of Update: 2020-10-06
level or level 3-4 TRAE, while 24 percent and 9 percent of patients who received chemotherapy, respectively. patients who received Opdivo plus chemotherapy, the rate of TRAE was consistent among different patient subgroups. "CheckMate-649
